drugset / Trial / NCT02565147

Bivalirudin Infusion for Ventricular Infarction Limitation

NCT02565147 ↗

Phase 3 Terminated 78 enrolled The Medicines Company
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate whether the use of bivalirudin will reduce extent of the damage done to the heart muscle in participants who suffered a heart attack, compared to the comparator treatment (heparin).

Timeline

Start
2014-12-19
Primary completion
2016-06-14
Completion
2016-06-14

Outcome

Missed primary endpoint

Stopped: “Futility at the interim analysis.”

registry analysis (superiority test); PPCI With Bivalirudin vs PPCI With Heparin; p = 0.7505; Wilcoxon Rank Sum Test NCT02565147 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bivalirudin Peptide 1.75 mg/kg —
Comparator Heparin Other / unclassified — —